Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?

被引：0
|
作者：
Arulananda, Surein
John, Thomas
机构：
[1] Olivia Newton John Canc Res Inst, Canc Immunobiol Lab, Heidelberg, Vic, Australia
[2] Austin Hlth, Dept Med Oncol, Heidelberg, Vic, Australia
[3] La Trobe Univ, Sch Canc Med, Heidelberg, Vic, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 01期
关键词：
CELL LUNG-CANCER; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; OSIMERTINIB;
D O I：
10.1016/j.jtho.2019.10.017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 14
页数：3
相关论文
共 50 条
  • [31] EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
    Gu, Weiguang
    Zhang, Hua
    Lu, Yiyu
    Li, Minjing
    Yang, Shuang
    Liang, Jianmiao
    Ye, Zhijian
    Li, Zhihua
    He, Minhong
    Shi, Xiaoliang
    Wang, Fei
    You, Dong
    Gu, Weiquan
    Feng, Weineng
    [J]. CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 841 - 850
  • [32] THE HIGH PLASMA CONCENTRATION OF GEFITINIB IN PATIENTS WITH EGFR MUTATED NSCLC CAN BE LONGER PROGRESSION-FREE SURVIVAL
    Miura, Hajime
    Sato, Kazuhiro
    Miura, Masatomo
    Asano, Mariko
    Okuda, Yuji
    Sano, Masaaki
    Watanabe, Hiroyuki
    Shioya, Takanobu
    Ito, Hiroshi
    [J]. RESPIROLOGY, 2013, 18 : 82 - 82
  • [33] Erlotinib/gefitinibDevelopment of resistance in EGFR-mutated NSCLC patients: 8 case reports
    [J]. Reactions Weekly, 2015, 1540 (1) : 130 - 130
  • [34] Effect of Different Timing of Local Brain Radiotherapy on Survival of EGFR-Mutated NSCLC Patients with Limited Brain Metastases
    Wang, Yu
    Wu, Shenghong
    Li, Jing
    Liang, Xiaohua
    Zhou, Xinli
    [J]. BRAIN SCIENCES, 2023, 13 (09)
  • [35] CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis
    Soo, R. A.
    Cho, B. C.
    Kim, J-H.
    Ahn, M-J.
    Lee, K. H.
    Zimina, A.
    Orlov, S.
    Bondarenko, I.
    Lee, Y-G.
    Ni, L. Yueh
    Lee, S. S.
    Lee, K. H.
    Pang, Y. K.
    Fong, C. H.
    Kang, J. H.
    Lim, C. S.
    Danchaivijitr, P.
    Lee, H.
    Park, S.
    Cicin, I.
    [J]. ANNALS OF ONCOLOGY, 2023, 34
  • [36] The efficacy and safety of furmonertinib in patients with advanced EGFR-mutated NSCLC and leptomeningeal metastases
    Han, Huan
    Tang, Hong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] A retrospective analysis of tolerability in EGFR-mutated NSCLC patients who received afatinib
    Koriyama, Haruki
    Yoh, Kiyotaka
    Kirita, Keisuke
    Umemura, Shigeki
    Matsumoto, Shingo
    Niho, Seiji
    Ohmatsu, Hironobu
    Goto, Koichi
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 137 - 137
  • [38] Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
    Kei Kunimasa
    Kazumi Nishino
    Yoshiharu Sato
    Masahide Mori
    Shoichi Ihara
    Hidekazu Suzuki
    Izumi Nagatomo
    Toru Kumagai
    Toshitaka Morishima
    Fumio Imamura
    [J]. Scientific Reports, 12
  • [39] Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
    Kunimasa, Kei
    Nishino, Kazumi
    Sato, Yoshiharu
    Mori, Masahide
    Ihara, Shoichi
    Suzuki, Hidekazu
    Nagatomo, Izumi
    Kumagai, Toru
    Morishima, Toshitaka
    Imamura, Fumio
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [40] Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs
    Leonetti, Alessandro
    Capula, Mjriam
    Minari, Roberta
    Mazzaschi, Giulia
    Gregori, Alessandro
    El Hassouni, Btissame
    Papini, Filippo
    Bordi, Paola
    Verze, Michela
    Avan, Amir
    Tiseo, Marcello
    Giovannetti, Elisa
    [J]. CELLS, 2021, 10 (06)
12345